TY - JOUR
T1 - Use of Ventricular Assist Devices and Heart Transplantation for Advanced Heart Failure
AU - Miller, Leslie
AU - Birks, Emma
AU - Guglin, Maya
AU - Lamba, Harveen
AU - Frazier, O. H.
N1 - Publisher Copyright:
© 2019 American Heart Association, Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/5/24
Y1 - 2019/5/24
N2 - There are only 2 treatments for the thousands of patients who progress to the most advanced form of heart failure despite the application of guideline-based medical therapy, use of ventricular assist devices and heart transplantation. There has been a great deal of progress in both of these therapies that have led to improved outcomes including significant improvement in survival and functional capacity. Heart transplantation offers the best short-and long-term survival for patients with end-stage heart failure, and the majority of these recipients achieve relatively limitless functional capacity for their age. However, the chronic shortage of available donors limits the number of recipients in the United States to an only 2500 patients/y or only a fraction of potential candidates. The significant improvement in outcomes now possible with durable ventricular assist devices has led to a significant increase in their use, which now exceeds the volume of heart transplants in the United States, with the greatest growth in use for those not considered to be candidates for heart transplantation, previously referred to as destination therapy. This article will review the substantial progress that has taken place for both of these life-saving treatment options, as well as the future directions.
AB - There are only 2 treatments for the thousands of patients who progress to the most advanced form of heart failure despite the application of guideline-based medical therapy, use of ventricular assist devices and heart transplantation. There has been a great deal of progress in both of these therapies that have led to improved outcomes including significant improvement in survival and functional capacity. Heart transplantation offers the best short-and long-term survival for patients with end-stage heart failure, and the majority of these recipients achieve relatively limitless functional capacity for their age. However, the chronic shortage of available donors limits the number of recipients in the United States to an only 2500 patients/y or only a fraction of potential candidates. The significant improvement in outcomes now possible with durable ventricular assist devices has led to a significant increase in their use, which now exceeds the volume of heart transplants in the United States, with the greatest growth in use for those not considered to be candidates for heart transplantation, previously referred to as destination therapy. This article will review the substantial progress that has taken place for both of these life-saving treatment options, as well as the future directions.
KW - cardiomyopathies
KW - heart failure
KW - mortality
KW - survival
KW - transplants
UR - http://www.scopus.com/inward/record.url?scp=85066829193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066829193&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.119.313574
DO - 10.1161/CIRCRESAHA.119.313574
M3 - Article
C2 - 31120817
AN - SCOPUS:85066829193
SN - 0009-7330
VL - 124
SP - 1658
EP - 1678
JO - Circulation Research
JF - Circulation Research
IS - 11
ER -